Family Care Center's TMS Protocol Shows Remission Rates Rivaling ECT

Event summary

  • Family Care Center's study, published in Transcranial Magnetic Stimulation, evaluated 600 adults with depression.
  • The novel TMS protocol resulted in over 80% of patients experiencing significant symptom improvement and over 50% achieving full remission.
  • Remission rates significantly exceed the ~30% typically seen with standard 30-day TMS courses.
  • The study suggests the bilateral TMS protocol is effective for patients with comorbid anxiety or PTSD.

The big picture

Family Care Center’s findings challenge the established treatment landscape for depression, particularly as ECT’s cognitive side effects limit its broader application. The study positions advanced TMS as a potentially safer and equally effective alternative, representing a significant opportunity to capture market share within the $10 billion+ mental health treatment market. The success hinges on regulatory approval and widespread clinical adoption, which will be influenced by reimbursement policies and clinician training.

What we're watching

Regulatory Approval
The FDA will likely scrutinize the bilateral TMS protocol given its deviation from standard TMS, and approval for broader use could be a key catalyst for Family Care Center’s growth.
Clinical Adoption
The pace at which other clinics adopt Family Care Center’s protocol will depend on reimbursement policies and the ability to train clinicians in the new technique.
Competitive Response
Other mental health providers and TMS device manufacturers will likely explore similar bilateral stimulation approaches, potentially intensifying competition in the TMS market.

Related topics

Mental Health